Cumberland pharmaceuticals announces fda clearance of ind for new treatment of idiopathic pulmonary fibrosis

Cumberland initiating phase ii fighting fibrosis™ clinical trial, newest program in cumberland's ifetroban pipeline nashville, tenn. , may 23, 2023 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq:cpix) today announced that the u.s. food and drug administration (fda) has cleared the investigational new drug application (ind) for a phase ii study in patients with idiopathic pulmonary fibrosis, the most common form of progressive fibrosing interstitial lung disease.
CPIX Ratings Summary
CPIX Quant Ranking